Go Back   NeuroTalk Support Groups > Health Conditions M - Z > Parkinson's Disease > Parkinson's Disease Clinical Trials

Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome.

IPX066, Phase III results

Reply
Thread Tools Display Modes
Unread 03-15-2011, 05:39 AM   #1
CarolynS
Member
 
Join Date: Nov 2008
Location: Gettysburg PA
Posts: 291
Default IPX066, Phase III results

Positive top-line results from IPX066 Phase III study in patients with PD

Published on March 15, 2011 at 12:04 AM

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson's Disease (PD) Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations. IPX066 is an investigational extended release (ER) CD-LD product. The ADVANCE-PD results demonstrated that IPX066 produced significantly improved control of motor symptoms as compared to IR CD-LD in multiple clinical measures in subjects with advanced PD.

The primary endpoint of this comparison study of IPX066 to IR CD-LD was the percentage of "off time" during waking hours. IPX066 demonstrated a 37% improvement from baseline for IPX066 vs. a 17% improvement from baseline for IR CD-LD (p<0.0001). "Off time" is the functional state when patients' medication effect has worn off and there is a return of Parkinson's symptoms.

The study enrolled 471 subjects on a stable regimen of IR CD-LD who were first entered into a dose-adjustment phase of their IR CD-LD, followed by a conversion to IPX066 after which they were then randomized to either IPX066 or IR CD-LD. Subjects converted to IPX066 experienced a reduction from baseline of more than 2 hours in total "off time" during waking hours, and this effect was maintained in the group then randomized to IPX066 during the blinded study portion. While the group treated with IR CD-LD achieved similar improvement during conversion to IPX066, "off time" worsened by 1.0 hours during double blind treatment with IR CD-LD (p<0.0001). In addition, during double-blind treatment, subjects experienced similar results in "on time" without troublesome dyskinesia with an increase of 1.9 hours for IPX066 compared to an increase of 0.8 hours for IR CD-LD as measured from study entry (p<0.001).
CarolynS is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
IPX066 Demonstrates Efficacy and Safety in ADVANCE-PD Phase III Study in Treatment of soccertese Parkinson's Disease 0 03-14-2011 03:24 PM
APEX-PD Phase III Trial of IPX066 in Parkinson's Disease, older news soccertese Parkinson's Disease 1 08-03-2010 10:32 AM
Impax Pharmaceuticals: Phase III trial of IPX066 in Parkinson’s Disease Stitcher Parkinson's Disease Clinical Trials 0 04-20-2009 10:10 AM
CERE-120 phase II trial results - shocking jeanb Parkinson's Disease 17 12-08-2008 10:43 AM
Ceregene announces positive phase 1 results ... aftermathman Parkinson's Disease 0 10-10-2006 08:53 AM


All times are GMT -5. The time now is 11:50 PM.
Brought to you by the fine folks who publish mental health and psychology information at Psych CentralMental Health Forums

The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider. Always consult your doctor before trying anything you read here.


Powered by vBulletin • Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.


All posts copyright their original authors • Community GuidelinesTerms of UsePrivacy Policy
NeuroTalk Archives